Rating Change
Roth Capital analysts initiated coverage on Castle Biosciences, Inc. (NASDAQ:CSTL) with a Buy rating on June 25, 2026.
new coverageNASDAQ:CSTL
Roth Capital Initiates Coverage on Castle Biosciences, Inc. (CSTL) with Buy
Rating Change Roth Capital analysts initiated coverage on Castle Biosciences, Inc. (NASDAQ:CSTL) with a Buy rating on June 25, 2026. Market Context Castle Biosciences, Inc.
Market Context
Castle Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $22.91 with a market capitalization of $1.1B.
Analyst coverage from Roth Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Castle Biosciences, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Castle Biosciences, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 25, 2026 | Roth Capital | Buy | N/A |
| May 13, 2026 | BTIG | Buy | N/A |
| May 07, 2026 | Baird | Outperform | N/A |
| Apr 20, 2026 | Canaccord Genuity | Buy | N/A |
| Feb 27, 2026 | Baird | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CSTL Stock Page
Frequently Asked Questions
What does a Buy rating mean for CSTL?
A Buy rating from Roth Capital reflects the analyst's outlook on Castle Biosciences, Inc. (NASDAQ:CSTL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CSTL forecast page.